Research To Practice | Oncology Videos

Latest Episodes:

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: KRAS-Mutant Non-Small Cell Lung Cancer (Companion Faculty Lecture) Aug 18, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Alexander Spira, including the following topics:

Incidence and spectrum of KRAS mutations in non-small cell lung cancer (NSCLC) (0:00)
Sotorasib for the treatment of NSCLC with a KRAS G12C mutation (2:06)
Clinical data evaluating adagrasib for the treatment of NSCLC with a KRAS G12C mutation (9:44)
Future directions in the care of patients with NSCLC with KRAS mutations (22:17)
Case: A man in his early 70s with relapsed NSCLC with a G12C mutation (26:26)
Case: A man in his mid 60s with newly diagnosed metastatic NSCLC with a KRAS G12C mutation (27:53)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: KRAS-Mutant Non-Small Cell Lung Cancer Aug 18, 2022

Show notes

Featuring perspectives from Dr Alexander Spira, including the following topics:

KRAS mutations in patients with non-small cell lung cancer (NSCLC) (0:00)
KRAS small-molecule inhibitors combined with targeted therapy or immunotherapy for patients with NSCLC (3:49)
KRAS small-molecule inhibitors in patients with NSCLC and brain metastases (10:52)
Future role of KRAS small-molecule inhibitors as adjuvant or neoadjuvant therapy for patients with localized NSCLC (12:21)
Comparing and contrasting KRAS small-molecule inhibitors for NSCLC (14:56)
Future directions in targeting KRAS and other mutations (20:32)
Using liquid biopsy to detect KRAS-mutated NSCLC (33:01)
Common misperceptions about targeting KRAS G12C in NSCLC (35:43)

CME information and select publications

Hepatobiliary Cancers | Meet The Professor: Optimizing the Management of Hepatobiliary Cancers — Part 2 Aug 17, 2022

Show notes

Featuring perspectives from Dr Robin "Katie" Kelley, including the following topics:

Introduction (0:00)
Case: A man in his mid 80s with newly diagnosed hepatocellular carcinoma (HCC) who has a partial response with atezolizumab/bevacizumab — Minesh Dinubhai Patel, MD (15:01)
Case: A man in his mid 60s with HCC and lung metastases (AFP = 30,000) who receives front-line atezolizumab/bevacizumab — Warren S Brenner, MD (30:17)
Case: A man in his mid 60s with metastatic HCC and rapid disease progression on first-line atezolizumab/bevacizumab — Shaachi Gupta, MD, MPH (34:56)
Case: A man in his early 80s with NASH liver cirrhosis and advanced HCC who develops proteinuria on atezolizumab/bevacizumab — Liudmila N Schafer, MD (39:09)
Journal Club with Dr Kelley (42:53)
Case: A woman in her early 70s with metastatic pancreaticobiliary cancer thought to be intrahepatic cholangiocarcinoma — Priya Rudolph, MD, PhD (48:39)
Case: A woman in her late 40s with intrahepatic cholangiocarcinoma and micrometastases in portal lymph nodes — Pavel A Levin, MD, PhD (59:13)

CME information and select publications

Gynecologic Cancers | Oncology Today with Dr Neil Love: Advances in Gynecologic Cancers from the 2022 ASCO Annual Meeting Aug 16, 2022

Show notes

Featuring an interview with Dr Brian Slomovitz, including the following topics:

Comparative efficacy and safety of commercially available PARP inhibitors for ovarian cancer (OC) (0:00)
Patient- and disease-specific considerations in the selection and sequencing of treatment for OC with BRCA mutations (11:39)
Mechanism of action of mirvetuximab soravtansine; recent efficacy and safety data with mirvetuximab for platinum-resistant OC from the SORAYA trial (15:13)
Potential integration of mirvetuximab soravtansine into the treatment algorithm for platinum-resistant OC; emerging data with niraparib/dostarlimab and adavosertib for OC (20:23)
Ongoing clinical trials evaluating tumor treating fields and upifitamab rilsodotin for OC (24:57)
Recent follow-up data with pembrolizumab/bevacizumab/chemotherapy for metastatic cervical cancer (CC) from the KEYNOTE-826 trial (27:30)
Efficacy and safety data with lenvatinib/pembrolizumab from the KEYNOTE-775 trial for endometrial cancer (EC); benefit of lenvatinib/pembrolizumab in subsequent lines of therapy (32:13)
Updated data with dostarlimab for microsatellite instability (MSI)-high EC; ongoing clinical trials evaluating immunotherapy versus chemotherapy alone for MSI-high EC (35:47)
HER2-low data with T-DXd for breast cancer and its potential role in therapy for EC; emerging role of mTOR inhibitors; ongoing investigations and unmet needs in OC, CC and EC (40:01)

CME information and select publications

Gynecologic Cancers | Oncology Today with Dr Neil Love: Advances in Gynecologic Cancers from the 2022 ASCO Annual Meeting (Companion Faculty Lecture) Aug 16, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Brian Slomovitz, including the following topics:

Recent data with PARP inhibitors alone and in combination with other agents as maintenance therapy for advanced ovarian cancer; recent data with novel agents (0:00)
Efficacy data with pembrolizumab/chemotherapy from the KEYNOTE-826 trial; biologic rationale for targeting tissue factor and emerging data with tisotumab vedotin for cervical cancer (16:45)
PFS2 data (disease progression on next line of therapy after first progression) with lenvatinib/pembrolizumab for advanced endometrial cancer; recent data with dostarlimab and mTOR inhibitors (23:58)

CME information and select publications

Gastroesophageal Cancers | Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 4 Aug 10, 2022

Show notes

Featuring perspectives from Dr Samuel Klempner, including the following topics:

Introduction (0:00)
Case: A man in his mid 70s with gastric adenocarcinoma and oligometastatic disease to the liver (PD-L1 10%, HER2-positive) — Ranju Gupta, MD (2:47)
Case: A man in his early 70s with locally advanced HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who undergoes chemoradiation therapy and surgery but develops progressive disease on adjuvant nivolumab and is now receiving CAPOX with trastuzumab (PD-L1 10%, microsatellite stable [MSS]) — Bruce Bank, MD (9:39)
Treatment of Microsatellite Instability-High Disease (20:46)
Case: A woman in her late 60s with GEJ adenocarcinoma metastatic to the liver (MSS, PD-L1 2%, HER2-negative) — Warren S Brenner, MD (36:32)
Case: A man in his late 50s with GEJ adenocarcinoma who receives neoadjuvant fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT), is found to have 8/18 positive nodes at surgery, receives adjuvant FLOT and currently has no evidence of disease (PD-L1
Case: A man in his early 50s with esophageal adenocarcinoma with an FDG-avid mediastinal node who undergoes chemoradiation therapy and definitive radiation therapy to the node (MSS, PD-L1 0%, HER2-negative) — Jennifer L Dallas, MD (48:55)
Case: A man in his mid 50s with a history of Barrett's esophagus with T1bNXM0 adenocarcinoma with signet cell features who undergoes endoscopic resection and declines esophagectomy — Matthew R Strickland, MD (53:11)
Case: A man in his early 60s with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Dr Gupta (56:58)

CME information and select publications

Head, Neck and Thyroid Cancers | Key Abstracts in Head, Neck and Thyroid Cancers from the 2022 ASCO Annual Meeting Aug 08, 2022

Show notes

Featuring an interview with Dr Ezra Cohen, including the following topics:

Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00)
Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06)
Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17)
Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47)
Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01)
Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08)
Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27)
Factors affecting response to immunotherapy (42:07)

CME information and select publications

Head, Neck and Thyroid Cancers | Key Abstracts in Head, Neck and Thyroid Cancers from the 2022 ASCO Annual Meeting (Companion Faculty Lecture) Aug 08, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Ezra Cohen, including the following topics:

Current standard therapy for head and neck cancer (0:00)
Emerging data from clinical trials in head and neck cancer (3:41)
Current standard therapy and recent research data in thyroid cancer (15:35)

CME information and select publications

Chronic Myeloid Leukemia | Meet The Professor: Optimizing the Management of Chronic Myeloid Leukemia — Part 2 Aug 04, 2022

Show notes

Featuring perspectives from Dr Daniel DeAngelo, including the following topics:

Introduction: Perspectives on chronic myeloid leukemia (CML) (0:00)
Asciminib — ASC4FIRST study (8:33)
Case: A woman in her early 60s with a PMH of Stage IA hormone receptor-positive breast cancer on adjuvant tamoxifen with newly diagnosed CML — Michael R Grunwald, MD (22:38)
Case: A man in his mid 40s with low-risk CML who achieves MR4 on imatinib but loses molecular response 3 months after discontinuing therapy — Shams Bufalino, MD (27:23)
Case: A man in his early 40s with CML on dasatinib who does not achieve treatment milestone (MR3) at 18 months but does at 24 months — Dr Grunwald (33:19)
Case: A man in his early 80s with CML who initially receives imatinib followed by nilotinib develops CHF and has a BCR-ABL of 0.8% (IS) — Namrata I Peswani, MD (37:33)
Case: A woman in her late 20s with CML that is resistant to multiple TKIs and therapy compliance concerns — Minesh Dinubhai Patel, MD (40:44)
Case: A woman in her early 40s who initially receives dasatinib for chronic-phase CML with a good response but then develops lymphoid blast crisis — Dr Grunwald (52:17)
Case: A woman in her mid 70s with CML who achieves MMR on nilotinib but then develops peripheral arterial occlusion after 9 years on therapy — Dr Grunwald (58:10)

CME information and select publications

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 Aug 03, 2022

Show notes

Featuring perspectives from Dr Ursula Matulonis, including the following topics:

Introduction: Journal Club with Ursula Matulonis, MD — Part 1 (0:00)
Case: A woman in her late 60s with primary peritoneal carcinoma with a germline BRCA mutation who underwent naturopathic therapy — Dana M Chase, MD (31:08)
Case: A woman in her late 70s with Stage IIIC fallopian tube cancer (homologous recombination proficient [HRp]) who underwent neoadjuvant chemotherapy — Paul DiSilvestro, MD (33:55)
Case: A woman in her late 60s with high-grade serous ovarian carcinoma and extensive peritoneal and omental metastases (HRp) who received chemotherapy and bevacizumab followed by niraparib — Vikas Malhotra, MD (38:50)
Case: A woman in her mid 70s with a germline BRCA1 mutation and bilateral breast cancer who experiences a complete response for 8 years to chemotherapy for metastatic ovarian cancer — Bruce Bank, MD (46:38)
Faculty Survey (49:46)
Journal Club with Dr Matulonis — Part 2 (54:02)
Case: A woman in her mid 40s who experienced multiple relapses of microsatellite instability-high clear cell ovarian cancer — Syed F Zafar, MD (57:38)

CME information and select publications